




Validation Data



Recombinant Human TNFRSF10D/DcR2/TRAIL-R4/CD264 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.



Immobilized Recombinant Human TRAIL at 2µg/mL (100 µL/well) can bind Recombinant Human DcR2 with a linear range of 15-60 ng/mL.



Recombinant Human TNFRSF10D inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED₅₀ for this effect is 1.8-7.2 ng/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.